Myriad Genetics, Inc. (MYGN)

전일 마감가:

$19.22

열려 있는:

$19.85

하루 거래량:

41,367

시가총액:

$1.74B

수익:

$753.20M

순이익/손실:

$-263.30M

주가수익비율:

-5.8036

EPS:

-3.36

순현금흐름:

$-184.20M

1주 성능:

+7.21%

1개월 성능:

-3.99%

6개월 성능:

+14.51%

1년 성능:

-10.96%

1일 변동 폭

$19.48

$20.09

52주 변동 폭

$13.82

$24.21

Myriad Genetics, Inc. Stock (MYGN) Company Profile

명칭

Myriad Genetics, Inc.

부문

Healthcare (1220)

산업

Diagnostics & Research (66)

전화

801-584-3600

주소

320 Wakara Way, Salt Lake City, UT

직원

2,400

트위터

@myriadgenetics

다음 수익 날짜

2024-05-14

최신 SEC 제출 서류

MYGN's Discussions on Twitter

Myriad Genetics, Inc. Stock (MYGN) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2023-12-21	재개	Piper Sandler	Neutral
2023-12-19	개시	Wells Fargo	Equal Weight
2023-12-14	개시	Guggenheim	Buy
2023-12-13	개시	Wolfe Research	Outperform
2023-07-05	재개	JP Morgan	Underweight
2023-05-23	업그레이드	Goldman	Sell → Buy
2023-01-18	업그레이드	Raymond James	Mkt Perform → Outperform
2022-10-06	개시	Stephens	Equal-Weight
2021-10-15	재개	Cowen	Market Perform
2021-06-15	개시	Raymond James	Mkt Perform
2021-06-03	개시	Goldman	Sell
2019-09-26	다운그레이드	BofA/Merrill	Neutral → Underperform
2019-08-14	다운그레이드	Piper Jaffray	Overweight → Neutral
2019-08-02	업그레이드	BofA/Merrill	Underperform → Neutral
2019-08-01	업그레이드	Barclays	Underweight → Equal Weight
2019-07-29	다운그레이드	Needham	Strong Buy → Hold
2019-07-09	다운그레이드	Cowen	Outperform → Market Perform
2019-03-12	재확인	Needham	Strong Buy
2019-01-03	개시	Needham	Strong Buy
2018-11-30	업그레이드	Goldman	Sell → Neutral
2018-10-10	업그레이드	Piper Jaffray	Neutral → Overweight
2018-07-11	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2018-03-21	업그레이드	Morgan Stanley	Underweight → Equal-Weight
2018-01-29	개시	Goldman	Sell
2018-01-22	재확인	Barclays	Equal Weight
2018-01-05	개시	BTIG Research	Buy
2017-10-02	재개	Leerink Partners	Mkt Perform
2017-08-09	재확인	Barclays	Equal Weight
2017-02-08	업그레이드	Ladenburg Thalmann	Sell → Neutral
2017-01-18	개시	Deutsche Bank	Sell
2016-10-10	다운그레이드	Ladenburg Thalmann	Neutral → Sell

모두보기

Myriad Genetics, Inc. 주식(MYGN)의 최신 뉴스

Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

GlobeNewswire Inc.

Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline

Zacks Investment Research

Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know

Zacks Investment Research

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

GlobeNewswire Inc.

Atossa (ATOS) Reports Positive Results From EVANGELINE Study

Zacks Investment Research

Myriad Genetics, Inc. (MYGN) 재무 분석

Myriad Genetics, Inc. (MYGN) 매출 2024

Myriad Genetics, Inc. (MYGN) 순이익 2024

Myriad Genetics, Inc. (MYGN) 현금흐름 2024

Myriad Genetics, Inc. (MYGN) 주당 순이익 2024